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Integrins induce expression of monocyte chemoattractant
protein-1 via focal adhesion kinase in mesangial cells
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Integrins induce expression of monocyte chemoattractant pro-
tein-1 via focal adhesion kinase in mesangial cells.
Background. Integrins are major adhesion receptors that
not only regulate cytoskeletal organization, but also trigger a
variety of intracellular signal transduction pathways. We exam-
ined the effects of increased extracellular matrix (ECM) accu-
mulation on monocyte chemoattractant protein-1 (MCP-1) ex-
pression, which is known to play an important role in the
progression of various glomerular diseases.
Methods. MCP-1 mRNA and protein expression in cultured
rat mesangial cells (MC) attached to ECM proteins were exam-
ined by reverse transcription (RT)-polymerase chain reaction
(PCR) and Western blotting, respectively. Phosphorylation of
focal adhesion kinase (FAK) was measured by Western blot-
ting. Effects of wild-type and dominant-negative FAK on
MCP-1 expression were examined by a transient transfection
assay.
Results. Cell adhesion to fibronectin-induced phosphoryla-
tion of FAK and MCP-1 mRNA expression in time- and dose-
dependent manners followed by increased MCP-1 protein ex-
pression. All integrin-interacting substrates (laminin and types
I, III, and IV collagens) also increased levels of FAK phosphor-
ylation and MCP-1 expression, whereas nonspecific adhesive
substrates (polylysine and concanavalin A) had no significant
effects. Overexpression of wild-type FAK increased phosphor-
ylation of FAK and expression of MCP-1 mRNA and protein,
whereas transfection of dominant-negative FAK abolished ad-
hesion-induced MCP-1 expression. Adhesion-induced expres-
sion of MCP-1 mRNA was inhibited by genistein and tosyl
phenylalanyl chloromethylketone (TPCK), suggesting that ty-
rosine kinases [e.g., FAK, and nuclear factor kappa B (NF-B)]
are necessary in this signaling.
Conclusion. Our results indicate that integrin-mediated cell
adhesion to the ECM can induce MCP-1 expression through
activation of FAK, and suggest a role for altered ECM deposi-
tion in the progression of glomerular diseases by affecting gene
expression.
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Glomerulosclerosis is the main pathologic feature of
progressive glomerulonephritis (GN) and is character-
ized by abnormal accumulation of mesangial extracellu-
lar matrix (ECM). Abnormal remodeling of the ECM
results from a complex process that involves increased
expression of growth factors and cytokines, and leads to
quantitative and constitutional changes in ECM compo-
nents such as fibronectin, laminin, and collagen types I,
III, and IV [1–4]. In addition, a correlation between glo-
merular expression of integrins (cell surface receptors for
ECM proteins) and their ligand matrix components is also
observed in various human and experimental GN [5–7],
suggesting that altered cell-ECM interaction, consequent
to enhanced expression of integrins and ECM proteins,
may contribute to the progression of GN.
Integrins are heterodimeric receptors composed of pairs
of  and  transmembrane subunits, and integrin-medi-
ated adhesion to the extracellular matrix plays important
roles in regulating formation of the cytoskeleton, cell sur-
vival, proliferation, and motility [8]. It has recently become
clear that integrins are involved in both cell adhesion and
signal transduction [9, 10]. Integrins can directly activate
many intracellular signaling events after stimulation by
ECM. Activation of intracellular signals includes tyro-
sine phosphorylation of focal adhesion kinase (FAK),
which binds to the 1 integrin cytoplasmic domain and
increases its tyrosine kinase activity upon binding to in-
tegrins [11]. Integrins and their cytoplasmic tails are in-
volved in forming large complexes of cytoskeletal pro-
teins and signaling molecules called focal adhesions that
include FAK and other signal transduction molecules,
such as p42/44 and p38 mitogen-activated protein (MAP)
kinases, phosphatidylinositol 3-kinase (PI 3-K), protein
kinase C (PKC), and c-Jun amino-terminal kinase (JNK)
[12]. Furthermore, integrins can function in an additive
or cooperative fashion with growth factors such as plate-
let-derived growth factor (PDGF) and angiotensin II
[13, 14]. Thus, many of the well-known signaling path-
ways identified previously for growth factors and cyto-
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kines are also activated by integrins and might lead to
the induction of expression of specific genes.
Monocyte chemoattractant protein-1 (MCP-1) is a
member of the chemokine family and has recently been
reported to have a high degree of specificity as a chemo-
tactic factor for monocytes/macrophages, and which plays
an important role in the progression of inflammatory
processes, including renal diseases [15]. In vitro studies
have shown that MCP-1 is produced by kidney cells such
as mesangial cells (MC) and tubular epithelial cells [16–18].
In fact, MCP-1 is implicated in the glomerular and tubulo-
interstitial injury of many renal diseases, including human
idiopathic glomerular diseases [19] and hypertensive kid-
ney [20], diabetic nephropathy [21, 22], and experimental
renal diseases [23, 24]. Furthermore, inhibition of MCP-1
reduces monocyte/macrophage infiltration in antibody-
induced experimental nephritis, indicating that MCP-1
might play an important role in the progression of renal
diseases [25].
Recent studies have elucidated the mechanisms that
regulate MCP-1 expression. Inflammatory cytokines and
growth factors, such as interleukin-1 and PDGF, can
trigger expression of MCP-1 through activation of sev-
eral signaling pathways, such as p42/p44 and p38 MAP
kinases [16, 26], PKC [27], activator protein-1 (AP-1)
[28], and nuclear factor kappa B (NF-B) [29]. In addi-
tion, our recent study showed that high pressure loading
of MC induced MCP-1 expression [16], suggesting that
mechanical strain such as glomerular hypertension itself
can up-regulate MCP-1 expression. Recently, it was re-
ported that cell adhesion to ECM proteins induces MCP-1
expression in hepatic stellate cells [30] and endometrial
stromal cells [31]. However, it remains unknown whether
integrin-mediated cell adhesion can stimulate MCP-1 ex-
pression in MC, and the molecular mechanism by which
cell adhesion induces MCP-1 expression is not yet eluci-
dated. In the present study, we provide evidence that
integrin-mediated cell adhesion to ECM proteins in-
duces MCP-1 expression through activation of FAK in
MC. These data invoke a novel mechanism for regulation
of MCP-1 in MC and support the possible role for abnor-
mal ECM accumulation in the pathophysiology of glo-




Human fibronectin, laminin, type I, III, and IV colla-
gens, poly-L-lysine, and concanavalin A were purchased
from Sigma Chemical Co. (St. Louis, MO, USA). Petri
dishes were coated by incubating with 10 g/mL or the
indicated amount of ECM proteins or adhesive sub-
strates in phosphate-buffered saline (PBS) for 1 hour at
37C, washed three times with PBS, and used for cell
adhesion assays. Monoclonal antibodies for FAK and
hemagglutinin (HA) were obtained from Transduction
Laboratories (Lexington, KY, USA) and Boehringer
Mannheim (12CA5; Indianapolis, IN, USA), respectively.
Polyclonal antibodies against Y397-phosphorylated FAK
and rat MCP-1 were from BioSource International (Ca-
marillo, CA, USA) and Santa Cruz Biotechnology (Santa
Cruz, CA, USA), respectively. Tyrosine kinase inhibi-
tor genistein, MEK1 inhibitor, PD98059, and PKC inhib-
itor, calphostin C, were purchased from Calbiochem (San
Diego, CA, USA). To inhibit NF-B activation, protease
inhibitor tosyl phenylalanyl chloromethylketone (TPCK)
(Sigma Chemical Co.) or antioxidant pyrrolidinedithiocar-
bamate (PDTC) (Sigma Chemical Co.) were used.
Cell culture
Glomerular MC from male Wistar rats were isolated
by the differential sieving method and identified by their
positive immunostaining for vimentin, smooth muscle–
specific actin, and negative staining for cytokeratins, fac-
tor VIII–related antigen, and leukocyte common antigen
(antibodies from Dako Corp., Carpinteria, CA, USA),
as described [32]. MC were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10% fetal calf serum (FCS), 100 U/mL penicillin, 100
g/mL streptomycin, and amphotericin B at 37C in a 5%
CO2 incubator. To synchronize the cells in quiescence,
MC were maintained in DMEM containing 0.5% FCS
for 24 hours prior to the experiments. MC were used
between passages 5 and 15.
Reverse transcription-polymerase chain
reaction (RT-PCR)
mRNA was extracted with the QuickPrep mRNA pu-
rification kit (Amersham Pharmacia Biotech, Bucking-
hamshire, UK). The first-strand cDNA was synthesized
from 25 ng of poly(A) RNA in 50 mmol Tris-HCl buffer
(pH 8.3) containing 200 ng random hexamers, 3 mmol
MgCl2, 400 U murine Moloney leukemia virus reverse-
transcriptase, 500 mol desoxynucleoside triphosphate
(dNTP), 15 mmol dithiothreitol (DTT), and 75 mmol
KCl in a final volume of 15 L for 1 hour at 37C using
a first-strand cDNA synthesis kit (Amersham Pharmacia
Biotech). Each sample was assayed for MCP-1 and glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA
using specific primers for polymerase chain reaction
(PCR) as described [16]: MCP-1; sense; 5-TATGCAG
GTCTCTGTCACGC-3, antisense; 5-AAGTGTTGA
ACCAGGATTCACA-3, GAPDH; sense; 5-TCCCT
CAAGATTGTCAGCAA-3, antisense; 5-AGATCC
ACAACGGATACATT-3. PCR was performed by in-
cubating 25 ng of the sample cDNA with 50 mmol KCl,
10 mmol Tris-HCl (pH 8.3), 1.5 mmol MgCl2, 0.01%
gelatin, 2.5 U Taq DNA polymerase, 400 mol dNTP,
and 40 pmol of primers in a final volume of 50 L. PCR
was performed for 26 cycles for MCP-1 and 22 cycles
for GAPDH under the following conditions: 1 minute
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at 95C, 45 seconds at 60C, and 45 seconds at 72C.
Primer sets for MCP-1 and GAPDH generated 595 bp
and 308 bp products, respectively. The samples were
subjected to agarose gel electrophoresis and stained with
ethidium bromide to visualize DNA bands, followed by
scanning densitometry (FB1200S; Canon, Tokyo, Japan).
Cell spreading assay
Cell spreading on extracellular matrix was quantified
as described previously [33]. Briefly, MC were allowed
to spread on Petri dishes coated with 10 g/mL fibronec-
tin for 3 hours and then fixed with 4% paraformaldehyde
in PBS. The percentage of cells spread on matrix was
determined by scoring at least 100 cells per sample in a
double-blinded fashion.
Western blotting
Cells plated on 10 g/mL fibronectin-coated dishes
were solubilized in radioimmunoprecipitation assay (RIPA)
buffer [50 mmol Tris, pH 7.4, 150 mmol NaCl, 1% Noni-
det P-40, 0.25% sodium deoxycholate, 1 mmol ethylene-
glycol tetraacetate (EGTA), 1 mmol phenylmethylsulfonyl
fluoride, 1 mmol sodium orthovanadate, 1 mmol sodium
fluoride, and a protease inhibitor mixture (Complete;
Boehringer Mannheim)]. Homogenates were clarified by
centrifugation at 15,000g for 15 minutes at 4C, and equal
amounts of total cell lysates (30 g protein) were ana-
lyzed by Western blotting using anti-phospho FAK
(1:2000), total FAK (1:1000), or MCP-1 (1:2000) antibod-
ies. Blots were visualized by the enhanced chemilumi-
nescence (ECL) reaction (Amersham Life Science).
Phosphorylation of FAK was determined as a ratio of
phosphorylated FAK against total FAK levels.
Plasmids and transfection assay
Plasmid-containing HA-tagged FAK (wild-type) was
kindly provided by Dr. J. Silvio Gutkind (National Insti-
tute of Dental and Craniofacial Research, National In-
stitutes of Health) [33]. The point mutant Y397F was
introduced into FAK by site-directed mutagenesis (Quick-
Change Site-Directed Mutagenesis Kit, Stratagene, CA,
USA) [34] and kindly provided by Dr. Kenneth M. Ya-
mada (National Institute of Dental and Craniofacial Re-
search, National Institutes of Health). Puromycin-resis-
tant plasmid pHA262pur was obtained from Dr. Heinte
Riele (Division of Molecular Carcinogenesis, The Neth-
erlands Cancer Institute, Amsterdam, The Netherlands).
Either wild-type or dominant-negative FAK (8 g) was
transfected into MC using the cationic liposome- (Lipo-
TAXI Mammalian Transfection Kit; Stratagene) medi-
ated transfection method together with pHA262pur (1g)
[16, 32]. To increase the expression of transfected genes,
5 mmol sodium butyrate was added to the culture me-
dium for 24 hours after transfection [34, 35]. Cells ex-
pressing HA-FAK were selected as described [16]. Briefly,
at 24 hours after transfection, cells were maintained for
two days in culture medium containing 1g/mL puromy-
cin, and cultured for an additional 24 hours in the regular
culture medium containing 0.5% serum without puromy-
cin. Equal expression of each HA-FAK plasmid was
confirmed by Western blotting using anti-HA antibody.
Statistical analysis
Data were expressed as mean  SD. Differences be-
tween groups were examined for statistical significance
using analysis of variance (ANOVA). A P value of less
than 0.05 denoted the presence of a statistically signifi-
cant difference.
RESULTS
Cell adhesion–induced MCP-1 mRNA expression
To confirm the accuracy of the mRNA quantity ampli-
fied by RT-PCR, PCR for MCP-1 and GAPDH was per-
formed by differential PCR cycles or by incubating serially
increasing amounts of mesangial cDNA synthesized from
25 ng of mRNA (data not shown), which revealed a
dose- and cycle-dependent increase in the PCR product.
We therefore amplified 25 ng of each mRNA for 26 cycles
for MCP-1 or 22 cycles for GAPDH in the following
experiments.
First, we examined the dynamics of the effects of cell
adhesion to the matrix on the expression of MCP-1 mRNA
expression (Fig. 1). MCP-1 mRNA was expressed at low
levels in serum-starved and nonadherent MC; however,
it rapidly increased from 30 minutes with a peak noted
at 3 to 6 hours. We also examined the effect of different
amounts of fibronectin on MCP-1 mRNA expression.
Although few cells were spread on fibronectin at 1 or
2.5 g/mL, cell spreading on fibronectin was significantly
increased when cells were spread on more than 5 g/mL
fibronectin (Fig. 2A). The increase in cell spreading was
similar to the increase in MCP-1 mRNA expression at
the same fibronectin concentration (Fig. 2B). Although
there were no significant increases in MCP-1 mRNA ex-
pression in cells spread on less than 2.5 g/mL fibronectin,
MCP-1 mRNA expression increased significantly when
the cells were spread on more than 5 g/mL fibronectin.
In addition, we examined MCP-1 protein expression
after adhesion to 10 g/mL fibronectin for the indicated
times (Fig. 3 A and B). MCP-1 protein levels in MC
increased significantly at 3 hours after adhesion, and
reached a peak level at 12 hours following MCP-1 mRNA
expression, reaching a peak level at 3 to 6 hours (Fig. 1).
In contrast, when cells were plated on polylysine, which
mediates integrin-independent cell adhesion, there was no
significant increase in MCP-1 protein expression (Fig. 3B).
Integrin-mediated expression of MCP-1 mRNA
We next examined whether cell adhesion–mediated
expression of MCP-1 was specific to integrin-mediated
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Fig. 1. Expression of MCP-1 mRNA by fibronectin. Cultured MC were
serum-starved for 24 hours and detached from the dishes by trypsin/
EDTA digestion. Cells were then plated on 10 g/mL fibronectin-
coated dishes for the indicated times in 5% bovine serum albumin
containing DMEM without serum. mRNAs (25 ng) obtained from cells
in suspension or cells plated on fibronectin (10 g/mL) for up to 24
hours were assayed for the expression of MCP-1 and GAPDH mRNA.
The amount of the PCR product was determined by scanning densitom-
etry and the relative ratio of MCP-1 to GAPDH band density was
calculated for each lane. Values represent mean MCP-1 mRNA expres-
sion levels expressed as the relative ratio of MCP-1 to GAPDH from
five independent experiments. Data are expressed as a percentage of
the amount of cells in suspension. Abbreviations are: MCP-1, monocyte
chemoattractant protein-1; MC, mesangial cells; EDTA, ethylenedi-
aminetetraacetic acid; DMEM, Dulbecco’s modified Eagle’s medium;
GADPH, glyceraldehyde-3-phosphate dehydrogenase; PCR, polymer-
ase chain reaction.
Fig. 2. Dose-dependence of fibronectin-induced MCP-1 mRNA ex-
pression. (A ) Dose-dependent cell adhesion to fibronectin. Cultured
MC were allowed to spread on petri dishes coated with the indicated
concentration of fibronectin for 3 hours. The percentage of cells spread
on fibronectin was determined as described in Methods. Data represent
the mean SD of four independent experiments. (B ) Dose-dependence
of fibronectin-induced MCP-1 mRNA expression. After cell spreading
on the indicated concentration of fibronectin for 3 hours, expression
of MCP-1 mRNA was analyzed by RT-PCR (suspension 	 100). Data
represent the mean  SD of four independent experiments. *P 
 0.01
vs. suspension. Abbreviations are: MCP-1, monocyte chemoattractant
protein-1; MC, mesangial cells; RT-PCR, reverse transcription polymer-
ase chain reaction.
cell adhesion. Cell interactions with ECM proteins through
integrin receptors can mediate transmembrane signal
transduction, including integrin-mediated tyrosine phos-
phorylation of FAK [9]. Phosphorylation of FAK was
determined as the ratio of phosphorylated FAK against
total FAK levels by Western blotting using anti-phospho
Y397 FAK and total FAK antibodies. Cell adhesion to
Fig. 3. Expression of MCP-1 protein by cell adhesion to fibronectin.
(A ) MCP-1 protein expression in cells in suspension or in cells plated
on fibronectin (10 g/mL) for the indicated times was analyzed by
Western blotting. (B ) The amount of MCP-1 protein was determined
by scanning densitometry and expressed as a ratio against the level of
cells in suspension. Values represent mean  SD of four independent
experiments. Symbols are: (), cells plated on 10 g/mL fibronectin;
(), cells plated on 10 g/mL polylysine. *P 
 0.05; **P 
 0.01; †P 

0.005 vs. suspension. MCP-1 is monocyte chemoattractant protein-1.
fibronectin rapidly increased FAK phosphorylation and
reached a peak level at 1 hour (Fig. 4). All integrin-
interacting matrix components, such as fibronectin, lami-
nin, and type I, III, and IV collagens significantly in-
creased FAK phosphorylation and MCP-1 mRNA ex-
pression (Fig. 5 A and B). However, the nonspecific
adhesive substrates, polylysine and concanavalin A, had
no significant effect on either MCP-1 mRNA expression
or FAK phosphorylation, suggesting that cell adhesion–
induced expression of MCP-1 depends on specific integ-
rin-mediated cell adhesion to ECM. Interestingly, al-
though the physiologic collagen, type IV, significantly
increased both MCP-1 mRNA expression and FAK
phosphorylation, compared to those of cells in suspen-
sion, the levels were less than those of the pathologic
collagens, types I and III (Fig. 5 A and B).
Role of FAK on integrin-mediated expression of
MCP-1 mRNA
FAK is one of the key molecules that transduces integ-
rin-mediated signals from the ECM. Cell adhesion–
induced FAK phosphorylation followed by MCP-1 ex-
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Fig. 4. Effects of cell adhesion to fibronectin on FAK phosphorylation.
MCP-1 protein expression in cells in suspension or cells plated on
fibronectin (10 g/mL) for the indicated times was analyzed by Western
blotting using anti-phospho Y397 FAK antibody. Relative FAK phos-
phorylation levels were determined from Western blotting by densito-
metric analysis and expressed as the relative ratio of phospho-FAK to
total FAK. Values represent mean  SD of four independent experi-
ments. *P 
 0.01 vs. suspension. FAK is focal adhesion kinase.
pression suggests that the expression of MCP-1 may be
a downstream event of FAK phosphorylation. Next, we
tested whether overexpression of wild-type FAK could
enhance cell adhesion–induced expression of MCP-1 and
whether expression of a dominant-negative form of FAK
could, in turn, attenuate cell adhesion–induced MCP-1
expression. We cotransfected HA-FAK or its mutant
with a plasmid containing the puromycin resistance gene
and selected transfectants for 2 days using puromycin
as described previously [16]. This puromycin selection
procedure routinely yielded 90% pure populations of
transfectants, according to fluorescence analyses using
HA markers. After selection by puromycin, the selected
cells were further analyzed for HA-tagged FAK con-
structs by Western blotting. As shown in Figure 6A
(lower panel), expression of wild-type FAK and domi-
nant-negative FAK (Y397F) were recognized by anti-
HA antibody. In addition, overexpression of FAK con-
structs resulted in increases in total FAK protein levels
by Western blotting using anti-total FAK antibody that
recognizes both endogenous and HA-FAK (Fig. 6A,
middle panel) as described previously [36]. Although
FAK phosphorylation was increased in cells transfected
with no FAK construct when cells were plated on fibro-
nectin, cells transfected with Y397F FAK exhibited
marked suppression of FAK phosphorylation (Fig. 6A,
upper panel, and Fig. 6B). Furthermore, overexpression
of wild-type FAK resulted in increased FAK phosphory-
lation. Levels of FAK phosphorylation were increased
to 348% and 476% in cells transfected without or with
wild-type FAK, respectively, while cells transfected with
Y397F FAK showed no significant increase in FAK phos-
phorylation (Fig. 6B). Furthermore, enhancement or
suppression of MCP-1 mRNA and protein were similarly
observed in cells transfected with wild-type or Y397F
FAK (Fig. 7 A to C), indicating that expression of MCP-1
is a downstream event of FAK activation.
Effects of various inhibitors on MCP-1
mRNA expression
FAK has been reported to activate downstream signal-
ing molecules such as MAP kinase, PKC, PI-3 kinase,
and NF-B [9, 37]. We further examined the downstream
signaling pathways below FAK, because it has been re-
ported that inflammatory cytokines, growth factors, and
mechanical forces can induce expression of MCP-1
through activation of several signaling pathways, such
as PKC [27], NF-B [29], and MAP kinase [16]. To inhibit
NF-B activation, MC were pretreated with the protease
inhibitor TPCK, which has been shown to inhibit in-
terleukin-1–inducible NF-B in MC and other cells [29].
Antioxidant pyrrolidine dithiocarbamate (PDTC) has
been shown to block phorbol ester–induced NF-B acti-
vation in several cell lines [29] and was also tested. Adhe-
sion-induced expression of MCP-1 mRNA was sup-
pressed totally by genistein, a tyrosine kinase inhibitor,
and TPCK, partially by PD98059, a MEK1 inhibitor, and
calphostin C, a PKC inhibitor, but not by wortmannin,
a PI3-kinase inhibitor (Fig. 8A). These results suggest
that tyrosine kinases such as FAK and NF-B are neces-
sary for integrin-mediated induction of MCP-1, and that
MEK1 and PKC are partially involved in this signaling.
Interestingly, PDTC did not attenuate MCP-1 induction,
similar to the observation that PDTC did not block IL-1–
induced NF-B activation, whereas TPCK completely in-
hibited such activation [29]. Furthermore, TPCK abol-
ished wild-type FAK-induced enhancement of MCP-1
expression, suggesting that NF-B is located downstream
of FAK in integrin-mediated MCP-1 expression (Fig. 8B).
DISCUSSION
Integrins mediate a variety of biologic processes, such
as cell adhesion, migration, and invasion, by functioning
as receptors for ECM molecules. In addition, integrin
interaction with ECM ligands also triggers transmem-
brane effects on the localization of signaling molecules,
as well as cytoskeletal molecules into focal adhesions
[12]. Thus, it activates signaling pathways and eventually
leads to regulation of gene expression, such as immediate
early genes and inflammatory cytokines [38, 39]. To our
knowledge, this study demonstrates for the first time
that integrin-mediated cell adhesion to ECM can induce
MCP-1 expression in MC, and that these effects of integ-
rins on MCP-1 expression depend on the activation of
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Fig. 5. Effects of various extracellular matri-
ces on MCP-1 mRNA expression and FAK
phosphorylation. (A ) Effects of various extra-
cellular matrices on MCP-1 mRNA expres-
sion. Cultured MC spread on indicated matrix
proteins (10 g/mL each) for 3 hours were
analyzed for MCP-1 mRNA expression by
RT-PCR. Data represent the mean  SD of
four independent experiments. *P 
 0.01;
**P 
 0.05 vs. suspension. (B ) Effects of vari-
ous extracellular matrices on FAK phosphory-
lation. Cultured MC spread on indicated ma-
trix proteins (10 g/mL each) for 3 hours were
analyzed for FAK phosphorylation by West-
ern blotting using anti-phospho Y397 FAK
antibody. Data represent the mean  SD of
four independent experiments. *P 
 0.01;
**P 
 0.05 vs. suspension. Abbreviations are:
MCP-1, monocyte chemoattractant protein-1;
FAK, focal adhesion kinase; MC, mesangial
cells; RT-PCR, reverse transcription polymer-
ase chain reaction.
Fig. 6. Effects of wild-type and dominant-negative FAK on FAK phos-
phorylation. (A ) MC were transfected without or with either HA-FAK
(Y397F) or HA-FAK (wild-type) plasmid together with puromycin-
resistant gene and transfectants were selected by puromycin as de-
FAK. These results suggest the importance of abnormal
ECM accumulation in modulating the pattern of synthe-
sis of a chemokine by glomerular MC.
FAK is a key molecule implicated in integrin signaling
pathways. The activation of integrins by cell binding to
ECM leads to the association of 1 integrin cytoplasmic
domain and N-terminal domain of FAK, followed by an
increase in FAK tyrosine phosphorylation and enhance-
ment of its kinase activity [9, 40, 41]. It has been suggested
that activation of FAK is required for the induction of
integrin-mediated MCP-1 activation in hepatic stellate
cells and endometrial stromal cells, because treatment of
cells with cytochalasin D, which disrupts the actin cyto-
skeleton and blocks tyrosine phosphorylation of FAK,
inhibits the cell adhesion–dependent increase in MCP-1
expression [30, 31]. In the present study, tyrosine phos-
phorylation of Y397 in FAK, which is a key tyrosine
phosphorylation site for full activation of FAK [40], was
observed prior to MCP-1 mRNA expression. Furthermore,
overexpression of wild-type FAK enhanced the matrix-
induced MCP-1 expression, while dominant-negative
FAK completely inhibited MCP-1 expression. Thus, ma-
nipulating the amount of phosphorylated FAK could re-
sult in changes in MCP-1 expression. These results strongly
scribed in Methods. Levels of FAK phosphorylation and amounts of
total FAK and HA expression were analyzed by Western blotting in
cells in suspension or in cells spread on fibronectin (10 g/mL) for 3
hours. (B ) Relative FAK phosphorylation levels were determined from
Western blotting by densitometric analysis and expressed as the ratio
against levels of cells in suspension without FAK constructs. Values
represent mean  SD of four independent experiments. *P 
 0.01 vs.
suspension. **P 
 0.05 vs. cells without FAK constructs plated on
fibronectin. Abbreviations are: FAK, focal adhesion kinase; MC, mesan-
gial cells; HA, hemagglutinin.
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Fig. 7. Effects of wild-type and dominant-negative FAK on MCP-1
mRNA and protein expression. (A ) MC were transfected without or
with either HA-FAK (Y397F) or HA-FAK (wild-type) plasmid together
with puromycin-resistant gene as described in Figure 7. Each transfec-
tant, either in suspension or plated on fibronectin (10 g/mL) for 3
hours, was assayed for MCP-1 and GAPDH mRNA expression by RT-
PCR. (B ) Relative MCP-1 mRNA expression levels were determined
by densitometric analysis and expressed as the ratio against levels of
cells in suspension. Values represent mean  SD of four independent
experiments. (C ) Each transfectant, either in suspension or plated on
fibronectin (10g/mL) for 12 hours, was also assayed for MCP-1 protein
expression by Western blotting. The amount of MCP-1 protein was
determined by scanning densitometry and expressed as a ratio against
indicate that integrin-mediated cell adhesion induces
MCP-1 expression in MC through activation of FAK.
In the present study, FAK phosphorylation was ob-
served within 10 minutes of cell attachment to the matrix,
reaching a peak level at 1 hour, while expression of MCP-1
mRNA and protein appeared after 30 minutes and 3
hours, respectively, reaching peak levels at 3 to 6 and
12 hours, respectively. Thus, cell adhesion to the matrix
triggered a sequential induction of FAK phosphorylation
and expression of MCP-1 mRNA and protein. The time
courses of MCP-1 mRNA and protein expression ob-
served in this study were similar to those of previous
studies in hepatic stellate cells, in which MCP-1 mRNA
appeared after 1 hour and peaked at 4 hours [30], and
in endometrial stromal cells, in which MCP-1 protein
was expressed from 12 to 24 hours [31].
Cells plated on all integrin-interacting substrates ex-
amined in this study (fibronectin, laminin, and type I,
III, and IV collagens) showed substantial induction of
FAK phosphorylation and MCP-1 expression, whereas
the nonspecific adhesive substrates, polylysine and con-
canavalin A, had no significant effects, indicating that
cell adhesion–induced expression of MCP-1 depends on
integrin-mediated cell adhesion to the ECM. Interest-
ingly, both FAK phosphorylation and MCP-1 expression
strongly increased in cells seeded on fibronectin, laminin,
and collagen types I and III when compared with cells
on collagen type IV. These results were similar to those
in endometrial stromal cells, in which fibronectin and
laminin induced increases of 6- and 4-fold in MCP-1
mRNA, respectively, whereas collagen type IV induced
an increase of only 2-fold [31]. Similar differences be-
tween collagen types I and IV were also reported by
Gonzalez-Santiago et al [42]; collagen type I showed an
increase in endothelin 1 expression when compared with
collagen type IV in endothelial cells. Although further
study is necessary to elucidate the mechanisms underly-
ing these differences, differential activation of integrin
subunits could be responsible for the observed differ-
ences between the ECM proteins tested in this study.
The integrin family is composed of pairs of  and 
subunits, which are selected from among at least 16 
and 8  subunits to form more than 20 different 
heterodimeric receptors on cell surfaces [10, 43]. Thus,
each subunit contributes to ligand specificity of the integ-
rins. Both 11 and 21 integrins are collagen recep-
the level of cells in suspension without HA-FAK plasmids. Values
represent mean  SD of three independent experiments. *P 
 0.01 vs.
suspension; **P 
 0.05 vs. cells without FAK constructs plated on
fibronectin. Abbreviations are: FAK, focal adhesion kinase; MCP-1,
monocyte chemoattractant protein-1; MC, mesangial cells; HA, hemag-
glutinin; GADPH, glyceraldehyde-3-phosphate dehydrogenase; RT-
PCR, reverse transcription polymerase chain reaction.
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Fig. 8. Effects of various inhibitors on MCP-1 mRNA expression. (A )
Cultured MC were pretreated with or without the indicated inhibitors
(calphostin C, 1 mol; PD98059, 25 mol; genistein, 5 mol; wortman-
nin, 500 nmol; TPCK, 25 mol; PDTC, 50 mol) for 30 minutes before
and during spreading on fibronectin (10 g/mL) for 3 hours. Expression
of MCP-1 mRNA was analyzed by RT-PCR. Relative MCP-1 mRNA
expression levels were determined as described in Figure 7. Data repre-
sent the mean  SD. *P 
 0.05 vs. suspension or fibronectin without
inhibitors; **not significant vs. suspension. (B ) Cells transfected with
or without HA-FAK (wild-type) plasmid were maintained in suspension
or plated on fibronectin (10 g/mL) for 3 hours with or without 25
mol TPCK. MCP-1 mRNA expression was assayed as described above.
*P 
 0.05; **P 
 0.001 vs. suspension, respectively; †not significant
vs. suspension. Abbreviations are: MCP-1, monocyte chemoattractant
protein-1; MC, mesangial cells; TPCK, tosyl phenylalanyl chlorometh-
ylketone; PDTC, pyrrolidinedithiocarbamate; RT-PCR, reverse tran-
scription polymerase chain reaction; HA, hemagglutinin; FAK, focal
adhesion kinase.
tors; however, they exhibit different relative affinities
depending on the substrate matrix. 11 integrin prefer-
entially adheres to collagen type IV, whereas 21 integ-
rin binds to collagen type I [44]. Both 11 and 21
bind to laminin as well as collagens, and 51 is a major
fibronectin receptor [43]. Thus, although receptors for
fibronectin, laminin, and collagens share structural com-
ponents with 1 integrin, which directly binds to FAK,
differences in the  subunit may account for the observed
response. The differences in intracellular signaling mole-
cules associated with different  subunit and/or expres-
sion levels of each  subunit might also be responsible
for the observed differences between collagen types I,
III, and IV. Because abnormal matrix remodeling char-
acterized by increased expression of fibronectin, laminin,
and collagen type IV, and de novo expression of collagen
type I and III are the main pathologic features of progres-
sive GN, it is interesting that collagen type IV, a normal
component of glomeruli, had a lesser effect on MCP-1
induction compared to the pathologic collagens, types I
and III.
MCP-1 is implicated in glomerular injury in various
human and experimental GN, diabetic nephropathy, and
hypertensive kidney disease [19, 20, 22, 45] by function-
ing as a major chemotactic factor for monocytes/macro-
phages [15]. Several signaling pathways are involved in
the regulation of MCP-1 expression, such as MAP ki-
nases, PKC, and NF-B, which can also be activated by
integrins [9, 37]. In the present study, adhesion-induced
MCP-1 mRNA expression was completely inhibited by
a tyrosine kinase inhibitor and TPCK, suggesting that
tyrosine kinases, such as FAK and NF-B are necessary
in integrin-mediated induction of MCP-1. Furthermore,
TPCK abolished wild-type FAK-induced enhancement
of MCP-1 expression, suggesting that NF-B is located
downstream of FAK in integrin-mediated MCP-1 ex-
pression.
CONCLUSION
We have demonstrated in the present study that stimu-
lation by ECM proteins per se, in addition to growth
factors and cytokines, can induce MCP-1 expression in
MC through the activation of the integrin/FAK cell adhe-
sion signal pathway. Although the classic perception of
MCP-1 is that its main function in glomerular diseases
is initial attraction of monocytes/macrophages, overex-
pression of MCP-1 also induces certain intracellular sig-
naling pathways that could lead to expression of various
cytokines such as interleukin-6. Considered together, it
is conceivable to view MCP-1 as an important mediator
in the progression of renal diseases. We speculate, based
on our data, that matrix accumulation might also play a
role in maintaining monocyte infiltration after the devel-
opment of ECM expansion in the subsequent phase of
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glomerular diseases, although such accumulation might
not be relevant to the initial monocyte infiltration into
glomeruli. Collectively, expansion of ECM might be
involved in the progression of glomerular diseases by
manipulating the number of infiltrating monocytes and
stimulation of cytokine gene expression through the in-
duction of MCP-1 expression.
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